

# FDA Indications

## Epclusa<sup>®</sup> (Sofosbuvir/Velpatasvir )

### Genotype 3\*

See Decision Trees for  
Treatment Forms

Patient Population	Medication(s)	Duration
Patients without cirrhosis or patients with compensated cirrhosis (Child-Pugh A)	Epclusa	12 weeks
Patients with decompensated cirrhosis (Child-Pugh B and C)	Epclusa + Ribavirin	12 weeks

**\*Preliminary data suggest that NS5A Genotype 3 RAV testing is recommended for all genotype 3 patients prior to treatment. Consult Liver Disease Specialist first.**